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Abstract
Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases,
with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in
the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were
recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of
the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera
venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the
pediatric population.
AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific
IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT
can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to
adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before
starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children
and caregivers’ preference and compliance.
In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated
food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents
a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the
effectiveness of AIT for patients with atopic dermatitis.
This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide
evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this
treatment for allergic children.
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Background
This consensus document was promoted by the Italian
Society of Pediatric Allergy and Immunology (SIAIP) to
implement the effective and safe use of AIT in children
with allergic diseases and to optimize clinical practice
recommendations for this treatment. A large number of
experts in the field of pediatric allergy and immunology
(academicians and territorial pediatricians) equally con-
tributed to this manuscript, that summarizes the SIAIP
consensus conference on AIT held in October 2013 in
Lipari, Italy, and updates the previous document [1, 2].
A comprehensive search of the medical literature was
carried out. References were identified by searches of
PubMed and online Cochrane databases. The search
strategies used the major keywords “allergy” and “im-
munotherapy” and all of the following, separately and in
combination: asthma/children/epicutaneuous immuno-
therapy/food allergy/management/oral immunotherapy/
rhinitis/rhino-conjunctivitis/treatment/subcutaneous im-
munotherapy/sublingual immunotherapy. We reviewed,
analyzed and considered only those studies published in
English language and involving pediatric populations
(age 0–18 years), published up to May 2016. The pub-
lished clinical trials were assessed by category of evidence
and used to determine the strength of recommendations
(Table 1), also according to other international documents
[3–6]. An algorithm summarizes the key issues for the ef-
fective use of AIT in allergic children (Fig. 1). The specific
recommendations indicate how to select eligible children
for AIT, provided that an IgE sensitization towards one or
more relevant allergens is documented, associated with
consistent symptoms of allergic rhinitis/conjunctivitis
and/or allergic asthma.
AIT can induce long-term effects after discontinuation
of the treatment and can modulate the natural course of
allergic disease by preventing the onset of new
sensitizations and the progression of respiratory allergies
[7]. In food allergy, although the available studies de-
scribed an effective clinical desensitization in the majority
of patients, this approach remains so far an experimental
strategy [8]. The same holds true for atopic dermatitis
(AD) associated with IgE-sensitization to inhalant aller-
gens [9]. This document also contains specific recommen-
dations for the prevention and therapeutic management
of adverse effects caused by AIT.
SCIT and SLIT are currently accepted as effective
treatments respiratory allergic diseases in children, and
some SLIT products were approved as drugs by EMA
and FDA [10, 11]. Concerning hymenoptera venom al-
lergies, this document does not analyze this issue, please
refers to the most recent and specific guidelines for
adults [12] and to the document developed by SIAIP in
2010 [2].
This consensus report provides recommendations and
suggestions to specialists for the use of AIT in pediatric
allergy, as derived by current literature. The document
does not replace, anyway, the clinical judgment that has
to be applied to each individual patient.
Table 1 Classification of evidence for allergen-specific immuno-
therapy used in the manuscript
Level of evidence
Ia Evidence from meta-analysis of randomized controlled studies
Ib Evidence from at least one randomized controlled study
IIa Evidence from well-designed controlled trial without randomization
IIb Evidence from at least one other type of experimental study
III Evidence from non-experimental descriptive studies, including
retrospective, case-control studies, cohort studies with controls
IV Evidence form opinions of respected authorities, based on clinical
experience, or reports of expert committees
Grades of recommendations
A: Directly based on Level I evidence. A certain therapeutic intervention
is strongly recommended.
B: Directly based on Level II evidence or extrapolated recommendations
from Level I evidence. A certain therapeutic intervention should be
carefully considered.
C: Directly based on Level III or IV evidence or extrapolated
recommendations from Level I or II evidence. There is significant
uncertainties about a certain therapeutic intervention.
Fig. 1 Proposed algorithm
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Choice of relevant allergens for allergen-specific
immunotherapy products
The European Medicines Agency (EMA) defines rele-
vant allergens as “allergens causing clinically relevant
effects in a significant proportion of allergic patients”
[13, 14]. The presence of relevant allergens in the
commercial preparations should be documented by
appropriate methods of quantification as the antibody
techniques or the mass spectrometry. The antibody
techniques for identifying the concentration of rele-
vant allergens are the following: the radioimmuno-
assay (RIA), the enzyme-linked immunosorbent assay
(ELISA), the radial immunodiffusion (RID), or the
rocket Immunoelectrophoresis [15–17]. The major al-
lergens are reported in Table 2.
Grass pollen allergens have a high cross-reactivity. Phl p
1 (Phleum pratense–Timothy grass) has similar reactivity
with Lol p 1 (Lolium perenne–Ryegrass), Poa p 1
(Poa pratensis–Meadow grass), Dac g 1 (Dactylis glo-
merata–Cocksfoot) and Hol l 1 (Holcus lanatus–Velvet
grass). The allergen content of each preparation used for
AIT should contain from 5 to 20 mcg of the major or
prevalent allergen for SCIT and 15–187 mcg for SLIT
[18]. Chemically modified allergens are named “aller-
goids”: these products maintain the desired immuno-
genicity, with a reduced allergenicity. The chemical
modification can be carried out both with molecules
binding allergens (formaldehyde, glutaraldehyde, algin-
ate) and with molecules that substitute a functional
group with another (potassium cyanate). This reaction
called carbamylation of allergenic extracts [19] confers
to the product a reduced IgE affinity and a partial re-
sistance to the proteolytic enzymes in the digestive
system. Modifications also include physical changes,
thus chemically modified allergens can be adsorbed
onto tyrosine, alum salts or alginate. Because of their
relevance, allergens should be accurately quantified in
preparations used for AIT. Currently, each manufac-
turing company has standard in-house reference ex-
tracts with known biological activity, with a relevant
variability in allergen content [14, 20, 21]. This condition
remains one of the main limits of AIT. Nowadays, prepa-
rations with a high concentration, well tolerated and safe,
have been included in the official pharmacopoeia, for
which the concentration of major allergens is provided in
mcg/ml. In this way, patients would be treated with ad-
equately standardized extracts.
The use of molecular diagnosis techniques [22] may
allow physicians to better identify whether children with
allergic respiratory symptoms are sensitized to major al-
lergens or to crossreactive molecules [23–25]. This is of
particular interest in patients who are sensitized to sev-
eral pollens, to prescribe AIT only for major allergens
[24, 25]. with the aim to increase the effectiveness of
AIT and to better select patients who need a treatment.
Furthermore, the molecular diagnostics could be a suit-
able instrument to implement the early therapeutic inter-
vention with AIT in children with respiratory allergy.
Allergen specific immunotherapy for respiratory
allergic diseases
Subcutaneous immunotherapy (SCIT)
Over the last 50 years, numerous controlled studies have
shown the efficacy of SCIT in the treatment of allergic
asthma and rhinitis [26, 27]. These data have been evalu-
ated in several meta-analyses and reviews. A Cochrane
analysis [28] included 51 studies for a total of 2871 par-
ticipants (1645 active, 1226 placebo), who underwent
AIT for seasonal allergic rhinitis for a duration from
3 months to 5 years. The meta-analysis showed a signifi-
cant clinical improvement in the AIT groups both in the
Table 2 The major genuine sensitizers from the relevant
allergenic sources
Allergen source Species Specific allergen
molecules
House dust
mite
Dermatophagoides
pteronyssinus
Der p 1
Der p 2
Dermatophagoides
Farinae
Der p 23
Der f 1
Blattella Germanica
(cockroach)
Der f 2
Bla g 1
Pet dander Felis domesticus (Cat) Fel d 1, Fel d 2
Canis familiae (Dog) Can f 1, Can f 3
Grass Pollen Phleum pratense
(Timothy grass)
Phl p 1, Phl p 5, Phl p 6
Cynodon dactylon
(Bermuda grass)
Cyn d 1
Lolium perenne (Ryegrass) Lol p 1, Lol p 5
Poa pratensis (Meadow) Poa p 1, Poa p 5
Dactylis glomerata (Cocksfoot) Dac g 1, Dac g 5
Holcus lanata (Velvet grass) Hol l 1, Hol l 5
Tree Pollen Betula verrucosa (Birch) Bet v 1
Olea europoea (Olive) Ole e 1
Alnus glutinosa (Alder) Aln g 1
Cryptomeria Japonica
(Japanese cedar)
Cry j 1
Cupressus arizonica (Cypress) Cup a 1
Weed pollen Ambrosia artemisifolia
(Ragweed)
Amb a 1
Artemisia vulgaris (Mugwort) Art v 1
Parietaria judaica
(Wall pellitory)
Par j 1
Par j 2
Molds Alternaria alternata Alt a1
Aspergillus Fumigatus Asp f 1
Cladosporium herbarum Cla h 1
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symptom score (data from 15 trials) and in the medica-
tion score (data from 13 studies). It was also shown an
improvement of immunological parameters and in the
quality of life. The meta-analysis excluded studies on
pediatric age, but in six studies were included also pa-
tients aged under 18 years, even if no specific outcomes
were evaluated in the pediatric population.
The efficacy of SCIT for the treatment of asthma was
evaluated in a meta-analysis including 101 studies (3792
patients) carried-out both in adults and in children but
no sub-analysis of the specific outcomes in the pediatric
groups was performed [29]. In particular, 42 studies of
AIT involved patients with mite allergy, 27 pollen allergy
(mostly grasses), 10 animal dander allergy, 2 Cladospor-
ium allergy, two latex allergy and six patients with mul-
tiple aeroallergens allergy. A significant reduction of
symptoms was found in patients treated with mite and
pollen AIT, while no significant improvement was re-
corded for animal dander or allergenic mixtures. Despite
the heterogeneity of the included studies, the overall re-
duction of symptoms (for all allergens) was significant
(SMD −0.59, 95% CI −0.83 to −0.35). The medication
scores and the bronchial hyper-reactivity were signifi-
cantly reduced, too. Out of the enrolled subjects, most
of them with mild to moderate asthma and normal base-
line spirometric parameters, no significant effect on lung
function was detected.
A systematic review, including RCTs on AIT for the
treatment of pediatric asthma and rhinitis [30], evaluated
13 studies on SCIT, for a total number of 920 children
suffering from asthma (7 studies), asthma with rhinitis/
rhino-conjunctivitis (5 studies) and rhino-conjunctivitis
(1 study). The allergens evaluated were house dust mites
in 8 of 13 studies, while in the remaining pollens and
moulds. Six RCTs including 550 patients evaluated the
effectiveness of SCIT on asthma symptoms, compared
to placebo or to pharmacotherapy. Studies with single-
allergen SCIT have shown efficacy in reducing symp-
toms (moderate evidence), while multiple allergens SCIT
(1 study) did not improve symptoms in subjects with
moderate to severe asthma, except in younger children
aged between 5 and 8 years. The effect on the use of
medication was evaluated in four studies for asthma and
in two for asthma with rhino-conjunctivitis. In all studies
it was detected a reduction in the use of medications.
Three studies, including 285 subjects suffering from al-
lergic rhinitis, showed an overall improvement of symp-
toms with a moderate to strong level of evidence.
Another review [31] analyzed 31 studies involving pa-
tients aged 3–18 years receiving SCIT for mites, grasses,
birch or Alternaria. The quality of the studies was
assessed using the Jadad score and the GRADE system
[32], and the review process was rigorously conducted,
putting together studies with different design: double-
blind placebo-controlled (DBPC), randomized clinical
trials (RCTs) and observational studies. Four studies on
grass pollen AIT provided high quality evidence: SCIT
induced a reduction in symptom score, a decrease in
skin reactivity and an increase in the threshold of spe-
cific nasal and/or bronchial provocation test. Long-term
efficacy up to 7 years after the end of treatment was also
reported [33]. Studies on Alternaria immunotherapy
(3 studies) showed similar results. Concerning mite
(22 studies) a reduction in symptoms scores, medication
use, skin reactivity and emergency room visits, with an in-
creased quality of life were observed. The effects on the
reduction of bronchial hyper-responsiveness and on the
improvement in lung function were less significant.
Sublingual immunotherapy
The available meta-analyses of the efficacy of SLIT in
children consistently showed a significant efficacy of the
treatment for patients with mild to moderate asthma.
Olaiguibel et al. [34] observed that the main effect was
the reduction in symptoms, less relevant than for medi-
cation usage. The allergen used was mainly mite. A fur-
ther meta-analysis [35] including nine studies (out of 73
examined) for a total of 441 children aged 3–18 years
with asthma (with or without allergic rhinitis) found a
significant reduction of both parameters examined:
symptoms and medication use. The authors emphasize
the considerable heterogeneity related to the methods of
evaluation of clinical asthma scores. Another meta-
analysis of ten studies including 484 children [36] re-
ported similar results.
The most recent studies of SLIT with birch pollen and
with grass pollen [37–39] were performed on a large
number of patients adequately randomized, using high-
dose preparations. These studies further confirmed the
efficacy of SLIT for the treatment of seasonal allergic
rhinitis and asthma. Overall, the reviews of the literature
on pediatric populations consistently support the efficacy
and safety of SLIT compared to placebo [40–42], and
only one review reported negative results. However, the
latter didn’t include all the eligible studies nor consid-
ered all relevant outcomes [43].
Recommendation 1
AIT should be considered in pediatric patients with
rhino-conjunctivitis and/or asthma with an ascertained
IgE-associated respiratory allergy, caused by clinically
relevant allergens. The decision to start the treatment
depends on several factors: the severity of the allergic
disease, the acceptance and adherence to the treatment,
the response to environmental prevention measures.
AIT should be always used in association with appropri-
ate pharmacotherapy (IaB).
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Selection of patients
AIT should be considered as therapeutic option in chil-
dren suffering from allergic rhinitis/conjunctivitis with/
without allergic asthma. Indeed, most allergic subjects
can potentially benefit from AIT, if carefully selected
with the appropriate allergy diagnostic tests. Since AIT
is allergen-specific, its efficacy and effectiveness depends
on a proper identification of the triggering allergen(s).
That means a proper recording of the clinical history
and ascertainment of environmental exposure, con-
firmed by diagnostic tests. The prescription of AIT de-
pends also on the severity and duration of symptoms,
that should be carefully evaluated individually (Table 3).
Essential parameters to assess the severity of the allergic
disease (in particular of asthma) are the need of add-
itional specialist visits and of the accesses to the emer-
gency department; the response to pharmacotherapy and
to allergen avoidance measures; as well as the recurrence
of symptoms impairing school or sport activities or alter-
ing sleep quality.
Before prescribing AIT, asthma symptoms should be
well-controlled. In children who can cooperate, the pa-
rameters of lung function have to be measured in order
to assess the level of asthma control. The prescription of
AIT is indicated when FEV1 is greater than 70% com-
pared to the predicted value, and uncontrolled asthma
remains the major absolute contraindication [44]. Al-
though there is no current general agreement on the ad-
ministration of AIT in younger children, some clinical
studies have shown the efficacy and safety of both routes
of administration (SCIT and SLIT) also in preschool
children [45–47]. It should be considered that repeated
injections of SCIT can be traumatic in small children,
and problems of communication and misunderstanding
especially in children aged < 4 years might occur [48].
Therefore, in this age group a careful risk/benefit evalu-
ation should be assessed individually for each patient.
In addition, AIT should be considered in those patients
who experienced severe or frequent medications’ side
effects or wish to avoid prolonged pharmacotherapy.
The pharmaco-economic analysis of studies on cost-
effectiveness shows that AIT does not seem more expen-
sive compared to the long-term pharmacotherapy [49, 50].
Recommendation 2
AIT should be considered as therapeutic option in chil-
dren suffering from allergic rhinitis/conjunctivitis with/
without allergic asthma also in preschool age (IbB).
Duration and adherence
The recommended duration of the treatment is at least
3 years [3–5]. A single study compared the efficacy of a
3-year versus 5-year course of AIT, showing an overall
similar efficacy of the two regimens [51]. Also, in a 15-
year study in adults with dust mite allergy, it was shown
that a 3-year duration of SLIT conferred a long-lasting
effect for five further years after discontinuation, and a
4-year course did slightly better [52].
According to the good clinical practices, it is
mandatory to:
– assess the effectiveness of AIT; after the patient
has reached the maintenance dose, the clinical
improvement should be assessed within a short
period.
– check the onset of any side effects;
– assess the adherence to the treatment;
– evaluate possible modifications to the current dosing
schedule.
The severity of the disease, the effectiveness and the
advantages of the treatment for the allergic children rep-
resent relevant criteria to decide if carrying on or dis-
continuing AIT. The causes underlying a poor or absent
improvement of symptoms usually may be: 1) incorrect
identification and treatment of the clinically relevant al-
lergens; 2) inadequate dose of allergen administered to
the patient; 3) too short duration of the therapy; and 4)
poor adherence to treatment. As opposite, once assessed
the effect of immunotherapy, the treatment should be
continued for not less than 3 years. The duration of the
treatment may be prolonged (5 years or more), depend-
ing on the clinical response of subjects. Many patients
experience a prolonged remission of symptoms after dis-
continuation of AIT [52–55] whereas others may have a
relapse of clinical manifestations. Currently, there are no
specific laboratory tests or biomarker that can distin-
guish patients who will relapse from those who would
have a prolonged clinical remission after discontinuing
AIT [56]. Therefore, the duration of AIT should be de-
cided by the pediatric allergist on an individual basis
Table 3 Indications for allergen-specific immunotherapy (AIT)
for pediatric allergic rhinitis, conjunctivitis with/without asthma
AIT should be considered for patients with evidence of specific IgE
sensitization towards one or few clinically relevant allergen(s).
The decision to start AIT depends on various factors including:
• Children’s (and caregivers) preference and acceptability
• Adherence to treatment
• Severity of symptoms and pharmacotherapy requirements
• Efficacy of avoidance measures (e.g. house dust mites, pollens)
• Asthma and co-existent rhinitis
Potential indications:
• Possible prevention of new sensitizations in mono-sensitized patients
• IgE-associated food allergy
• Extrinsic atopic dermatitis
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taking in account benefits, possible risks and the agree-
ment of the patient/family. The clinical improvement is
closely related to the adherence to AIT. Allergen-
specific immunotherapy is a prolonged treatment, thus
educating the allergic child and his/her family remains a
basic aspect to increase the adherence [48, 57, 58].
Recommendation 3
The treatment should last at least 3 years (IbA). More
prolonged treatment gave little adjunctive benefit in
adults (Ib). Adherence is a pre-requisite for the AIT effi-
cacy. Pediatric allergist must inform and properly edu-
cate children and their families in order to obtain the
best possible adherence (IbA).
Safety aspects
The absolute contraindications to AIT are concomitant
malignancies, severe immune-associated diseases (e.g.
severe immunodeficiencies), chronic and invalidating
disorders and uncontrolled (symptomatic) asthma [44].
The safety of SCIT in children was evaluated in several
systematic reviews. According to the available literature,
systemic side effects are rare, but more frequent with
SCIT than with SLIT [59–61]. The more recent system-
atic reviews [61] reported a high rate of local side effects
for SLIT, but almost always mild, self-resolving and
short-lasting. The local reactions usually were oral prur-
itus and swelling, oedema of lips, local paresthesia, ab-
dominal pain, and diarrhea. Systemic reactions (urticaria,
asthma, conjunctivitis) were anecdotal among SLIT pa-
tients and no fatality was described so far.
The lack of a standardized and homogeneous grading
system in reporting and classifying the adverse events
among the different studies is actually a strong limita-
tion to define the real severity of each reaction.
Nevertheless, a grading system to classify the adverse
events of both routes of administration has been sug-
gested [60, 61] (Tables 4 and 5), also according to the
MedDRA definitions [62].
Some general rules should be applied when using AIT:
SCIT
– Assess the patient’s general condition.
– Do not administer AIT in case of exacerbation of
asthma.
– Do not administer AIT in case of severe
exacerbations of rhinitis, urticaria, atopic dermatitis.
– Consider dose adjustment or temporary
discontinuation in the case of recent systemic
reactions such as asthma, urticaria, and rhinitis.
– Discontinue AIT on ascertained anaphylactic
reaction.
– Adjust temporary the dose in case of injection-site
granuloma (mid-postero-lateral upper arm).
– Based on common sense precautions, starting SCIT
during the pollen season (when there is a risk of
symptom exacerbation) should be avoided.
Nonetheless, the recent literature reports that a co-
seasonal initiation of AIT and the reduction of doses
do not increase the risk of adverse events [63].
– Consider a downward dosage adjustment during the
peak pollen season if symptoms worsen.
– SCIT must always be administered by a trained
physician/nurse.
– maintain close observation for at least half an hour
after injection,
Epinephrine remains the treatment of choice in the
case of moderate-severe immunotherapy-induced
systemic reactions. This treatment should be always
available, since the delayed administration of adrenaline
Table 4 Grading of systemic side effects (SCIT and SLIT) (simplified from 59)
GRADE 1 GRADE 2 GRADE 3 GRADE 4 GRADE 5
Symptoms/signs of one
organ/system
● Cutaneous: generalized
pruritus, urticaria, flushing.
OR
● Angioedema (not tongue,
laryngeal or uvular)
OR
● Upper respiratory: rhinitis,
cough
OR
● conjunctivitis
Symptoms/signs of one
organ/system
OR
● Lower respiratory: asthma,
cough with wheezing, chest
tightness, shortness of breath.
Fall <40% PEF, responding
to SABA
OR
● Gastrointestinal: abdominal
cramps, vomiting, or diarrhea
OR
● Uterine cramps
● Lower respiratory
Asthma (eg, >40% fall PEF
or FEV1) NOT responding to
an inhaled bronchodilator
OR
● Upper respiratory: laryngeal,
uvula, or tongue edema with
or without stridor
● Lower or upper respiratory:
respiratory failure with or
without loss of consciousness
OR
● Cardiovascular: hypotension with
or without loss of consciousness
Death
Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4. Note: Children with anaphylaxis seldom convey a sense of impending doom
and their behavior changes may be a sign of anaphylaxis; eg, becoming very quiet or irritable and cranky. Scoring includes a suffix that denotes if and when
epinephrine is or is not administered in relationship to onset of symptom(s)/sign(s) of the SR:a, 5 min; b, >5 min to 10 min; c: >10 to 20 min; d:>20 min; z,
epinephrine not administered. The final grade of the reaction will not be determined until the event is over, regardless of the medication administered. The final
report should include the first symptom(s)/sign(s) and the time of onset after the allergen immunotherapy administration and a suffix reflecting if and when
epinephrine was or was not administered, eg, Grade 2a; rhinitis:10 min. Symptoms occurring within the first minutes after the administration may be a sign of
severe anaphylaxis.
Final Report: Grade a–d, or z__________ First symptom(s)/sign(s)___________ Time of onset of first symptom_____________
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is one risk factor for fatalities during anaphylaxis [64]. In
children, intramuscular injection in the lateral thigh
(vastus lateralis muscle) of adrenaline (aqueous epineph-
rine 1:1000 dilution [1 mg/ml]: 0.01 ml/Kg; maximum
0.5 mg/dose (=0.5 ml) with a 5-min interval between in-
jections, as necessary) provides rapid bioavailability with
a peak plasma concentration within 10 min, higher safety
profile and longer duration of action.
Further equipment rapidly available should be oral,
intravenous/intramuscular H1 antihistamines and
corticosteroids; inhaled salbutamol with spacer, oxygen
6–8 L/min by ventimask, intravenous fluid support
with rapid infusion (10–15 min) of normal saline up to
5–10 ml/Kg. Intramuscular adrenaline must be always
available.
SLIT
– Assess the patient’s general condition.
– Do not administer AIT in case of exacerbation of
asthma.
– Do not administer AIT in case of severe
exacerbations of rhinitis, urticaria, atopic dermatitis.
– Consider temporary discontinuation of the
treatment in case of any mouth ulcers or dental
procedures.
– Carefully evaluate if commencing an
immunotherapy treatment during the pollen season
in patients with pollen allergy.
– Provide patients and their parents clear information
about how to self-administer SLIT.
Recommendation 4
Allergen specific immunotherapy in children is well
tolerated (Evidence level: Ia). In clinical practice the
management is different in case of perennial (mites) or
pollen allergens. Immunotherapy can be initiated also in
pre-school children if indicated. Indications are similar
to those established for other age groups (III B).
Long term and preventive effects of allergen
specific immunotherapy
The natural history of respiratory allergies (allergic rhin-
itis and asthma) usually follows a reproducible pathway,
the so called “atopic march” [65]. Concerning respiratory
allergy, rhinitis is a well-known independent risk factor
for the development of asthma and the bronchial
hyperreactivity which is often an accompanying symp-
tom represents an additive risk factor [66–70].
Several experimental data suggest that AIT can modify
the natural history of allergic respiratory diseases. The
effectiveness in altering the natural course of respiratory
allergies was historically documented in an observational
study [71]. After 14 years, children having received SCIT
developed less asthma than children treated with
pharmacotherapy alone. After more than 40 years, the
Preventive Allergy Treatment (PAT) study [72], a pro-
spective randomized controlled trial, tried d to evaluate
whether SCIT, compared to pharmacotherapy alone,
could prevent the development of asthma in children
with seasonal allergic rhino-conjunctivitis due to grass
pollen and/or birch allergy. The study showed that chil-
dren treated with SCIT had a reduced risk of developing
asthma with a significant positive odds ratio (OR). In-
deed after 3 years of study, among the 151 children
without asthma at the enrollment, 19/79 of the SCIT pa-
tients developed asthma versus 32/72 of the control
group. This preventive effect was still present 2 and
7 years after discontinuation of the treatment, support-
ing the hypothesis of a preventive effect of AIT [73, 74].
However, some important methodological criticisms
need to be disclosed, such as the lack of the double-blind
design, the presence of children with asthma during the
enrollment phase, the absence of data on the severity of
asthma of the control group. Two other randomized trials
investigated the preventive effect of AIT on the develop-
ment of asthma. The first study evaluated 99 children
aged 5 and 14 years with allergic rhinitis due to grass
pollen [75]. After 3 years 18 of the 44 children in pharma-
cotherapy (controls) had developed asthma, compared to
eight of the 45 children treated with SLIT. In this study,
the risk of developing asthma resulted 3.8 fold increased
in controls respect to SLIT treated children. Another
study [76] evaluated 196 of 216 enrolled children aged 5
and 17 years with allergic rhinitis with or without inter-
mittent asthma. Participants were randomized into two
groups with a proportion of 2:1 for SLIT versus pharma-
cotherapy alone. After 3 years, the onset of persistent
asthma was recorded in 2/130 children (1.5%) of the SLIT
group compared to 19/66 (30%) of the control group (OR
0.04; 95% CI, 0.01–0.17). AIT was demonstrated to have a
preventive effect also on bronchial hyper-reactivity. A ran-
domized double-blind placebo controlled trial enrolling 30
children with asthma due to Parietaria showed that SLIT
Table 5 Local side effects from SLIT (simplified from 60)
DESCRIPTION GRADE 1: mild GRADE 2: moderate GRADE 3: severe
Pruritus, swelling of mouth, tongue or lips; throat irritation;
nausea; abdominal pain; vomiting; heartburn; uvular edema
Not troublesome AND
No treatment required AND
No discontinuation
Troublesome OR
Requiring symptomatic
treatment AND
No discontinuation
Grade 2 AND
treatment discontinued
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has a preventive effect on bronchial hyper-responsiveness
to methacholine test during the pollen season: in the
active group the degree of bronchial reactivity during
the second pollen season was similar to the baseline
values [77].
Currently, two double-blind placebo-controlled ran-
domized studies were set up focusing the preventive ef-
fect of AIT on the development of asthma in children.
The first one, on primary prevention of respiratory al-
lergy was interrupted due to the poor adherence of
younger children and problems related to ethical com-
mittees [78]. In the second study, children aged between
5 and 14 years with allergic rhinitis (but not asthma)
due to grass pollen were randomized to receive treat-
ment with SLIT or placebo. The aim of this study, cur-
rently ongoing is to evaluate the development of asthma
after 5 years from the beginning of AIT [79]. The results
of these preventive intervention studies will provide evi-
dences on the effective role of AIT in the primary and
secondary prevention of allergic diseases. However,
asthma is well recognized as a multifactorial disease with
characteristics that depend on many variables, such as
infections, bronchial reactivity, allergy, indoor and envir-
onmental pollution, comorbidities, which have led in the
recent years to a better identification of different pheno-
types and endotypes of this disease. Therefore, further
RCTs are needed to verify the preventive effect of AIT
on asthma onset in children with allergic rhinitis and/or
IgE-associated atopic dermatitis.
As for the risk of developing new allergic sensitizations
over the years, it is well known that the sensitization
may occur in the first years of life, frequently with IgE
production against foods, then against environmental al-
lergens (house dust mites) and finally pollens, such as
grasses, Parietaria or birch. Nevertheless, many children
may first experience allergy to mites, without presenting
a previous food allergy; and, also the sensitizations to
pollens or molds like Alternaria may appear without
prior allergies [80, 81]. There is evidence suggesting that
the preventive effect of AIT on the natural history of al-
lergic respiratory diseases does not affect only the pro-
gression towards asthma, but also on the appearance of
new sensitizations. In one study, 22 children aged 4–6
years and monosensitized to house dust mites were
treated with SCIT and pharmacotherapy and compared
with 22 peers treated with pharmacotherapy alone. After
3 years, 10/22 children (45%) of the SCIT group did not
show new sensitizations, while all of the 22 controls de-
veloped one or more new sensitivities [82]. Another
non-randomized prospective study provided similar re-
sults [83]. Seventy-five of 138 children (aged 5–8 years)
monosensitized to mites affected by intermittent asthma
were treated for 3 years with SCIT and pharmacotherapy
and the remaining with pharmacotherapy alone controls.
Three years after the discontinuation of SCIT, 75.4% of
children in the SCIT group did not develop new sensiti-
zations, while only 33,3% of the controls remained
monosensitized.
Several studies conducted in the last 20 years have
documented that the clinical benefits of AIT can last
long after the discontinuation of the treatment [7]. The
long-term effects have been observed for both SCIT and
SLIT, and represent an exclusive prerogative of AIT. In-
deed, none of the currently available pharmacological
treatments for respiratory allergies has shown a compar-
able long lasting effectiveness after its discontinuation,
nor a potential in modifying the natural history of these
diseases [55, 84–88]. The results of controlled clinical
trials carried out with both routes of administration
(subcutaneous and sublingual) have confirmed that AIT,
as etiological therapy for IgE-associated respiratory dis-
eases, can maintain improvement in symptoms even
after its discontinuation. Also in these cases the studies
are heterogeneous in duration, patient selection, and
largely focused on subjects allergic to grasses. To date,
evidence on preventive and long-term effects of AIT is
suggestive, but not definitive yet.
Recommendation 5
Despite of the methodological limitations, the currently
available studies have shown that an early therapeutic
intervention with AIT, when the child is at the early
stages of the respiratory disease and still mono- or
pauci-sensitized, can be evaluated as therapeutic option
in the clinical practice. The long-term efficacy after the
discontinuation of the treatment can be considered as a
unique and distinctive characteristic of AIT (IIaB).
Allergen-specific immunotherapy for food
allergy (FA)
FA remains a growing health issue, with an estimated
prevalence of about 6–8% in the pediatric population
[89–92]. Nonetheless, estimating the true prevalence of
FA remains difficult, depending on the local nutritional
habits, different phenotypes, and unavoidable inaccuracy
in diagnosis. The definition of FA assumes that symp-
toms caused by the ingestion of a food represent the ef-
fect of an immune response, which can result either
from IgE- or non-IgE mediated mechanisms or a com-
bination of both [91, 92]. The most frequently causative
foods are cow’s milk (CM), hens’ egg (HE) and peanut,
distantly followed by fish, shellfish, meat and wheat. FA
should be suspected on medical history and results of in
vivo and in vitro allergy tests, but oral food challenge,
possibly in a double blind fashion, still remains the
cornerstone in the diagnostic process. The only effective
treatment is the complete allergen avoidance in associ-
ation with the use of emergency medications to be used
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when accidental reactions occur. However, a complete
elimination diet is difficult to perform, especially for
common foods as CM and HE, which can be present in
food as hidden allergens. All these aspects heavily affect
the quality of life of children and caregivers [93–96]. In
this context, considering the potential desensitizing ef-
fects of allergen administration, several therapeutic strat-
egies targeting the IgE-associated FA reactions were
investigated, including oral immunotherapy (OIT) and
SLIT, to achieve desensitization. OIT and SLIT for FA
involve the administration of slowly increasing doses of
the allergen source until the food is tolerated at usually
dietary doses. This approach can confer protection
against accidental allergic reactions and contribute to
improve nutritional status and quality of life of the af-
fected patients [97]. It is not clearly defined if when
desensitization has been achieved, a permanent toler-
ance persists, independent of the regular ingestion of the
responsible food.
Many clinical trials performed with cow milk, egg
and peanuts are nowadays available, as reviewed in
numerous articles [98–107]. All the published trials
(Tables 6, 7 and 8), consistently show that an effective
desensitization can be obtained in 60–80% of children,
that about 10% of children undergoing desensitization
must stop the procedure due to severe adverse events and
that a permanent (or long-lasting) tolerance is achieved in
about 50% of the patients with a previous successful
desensitization [108]. Oral or sublingual desensitization
procedures for food allergy still remain an experimental
model to be used only under medical supervision and/or
in research context [109, 110].
Recommendation 6
Based on current evidence, we recommend to perform
food OIT/SLIT only in highly specialized centers and
under strict medical supervision after the informed con-
sent has been obtained from parents (IaA).
Allergen-specific immunotherapy for “extrinsic”
atopic dermatitis (AD)
AD is a chronic inflammatory skin disease deriving from
a complex interaction among genetic factors, impaired
skin barrier function, immune dysregulation and expos-
ure to various environmental allergens and infectious
agents [111, 112]. Most patients have increased total IgE
and are sensitized to aeroallergens (mainly house dust
mite), this defining the “extrinsic” form of AD. In such
cases, the exposure to allergens may exacerbate the dis-
ease [110, 111]. It is still controversial whether AIT may
be beneficial for patients with AD. Considering the clin-
ical effectiveness of AIT in IgE-associated allergic dis-
eases, several trials, often uncontrolled, investigated the
efficacy of AIT for patients with “extrinsic” AD and
reported overall controversial results [9, 113, 114]. It is
true that some proofs of clinical efficacy in extrinsic AD
are available [114, 115], but no clear indication or rec-
ommendation can be made. Also in this case, the use of
AIT in AD remains experimental, and the indications
are confined to allergic rhinitis/asthma, when concomi-
tant AD is present.
Recommendation 7
The efficacy of AIT in children and adults with AD is
still controversial. A more precise selection of clinical
phenotypes (e.g., presence of IgE-sensitization to house
dust mites, concomitant respiratory allergy, evidence of
a cause-effect relationship between IgE-sensitization
and AD exacerbation) may help identifying patients
with extrinsic AD who could benefit from AIT (Evi-
dence Level: III).
Regulatory aspects of allergen-specific
immunotherapy
The European Academy of Allergy and Clinical Immun-
ology (EAACI) has recently published a declaration which
supports the key role of AIT in the treatment of IgE-
associated allergic diseases and calls upon Europe’s policy-
makers to promote awareness of the effectiveness of AIT
and funding for AIT research. For many years most aller-
gen products have been marked in European countries as
“named patients products” (NPP), which only require to
be prepared in compliance with Good Manufacturing
Practice to get a marketing authorization. In addition,
NPP don’t require independent evaluation of quality, effi-
cacy, and safety and there is no demand for manufacturer
to notify adverse events. The regulatory scenario for AIT
changed with the Directive 2001/83/EC and 2003/63/EC
of the European Parliament which recognize that: 1) aller-
gens are medicinal products capable to identify or induce
a specific acquired alteration in the immunological re-
sponse to a sensitizing agent; 2) as medicines produced
with an industrial process, allergens require a marketing
authorization (AIC) in Europe according to the proce-
dures established for all drugs (i.e., centralized, mu-
tual recognition, decentralized, or national) and
following a clinical development through all phases of
RCTs [14, 116]. The European Medicines Agency
(EMA) has recently released specific guidelines for
designing clinical studies on the development of products
for AIT [117]. Clinical trials in the pediatric population
should also follow the EMA pediatric investigation plan
(PPI) ([118], https://www.clinicaltrialsregister.eu/ctr-
search/trial/2012-005678-76/IT). However the Directive
2001/83/EC of the European Parliament has also estab-
lished some exceptions (e.g. prescription for individual pa-
tients under the direct doctor responsibility) which still
allowed the use of allergen products as NPP instead of
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registered medicines (https://www.clinicaltrialsregister.eu/
ctr-search/trial/2012-005678-76/IT). Furthermore, in
Europe every pharmaceutical manufacturer provides its
standardization of allergen extracts for AIT. This legitim-
ate assertion of autonomy in research and production of
AIT have resulted in significant discrepancy in the aller-
gen concentration in extracts of different manufacturers.
The use of registered products for AIT in the pediatric
population could represent a new era for patients suffer-
ing from IgE-associated allergic diseases. The allergen
manufacturer should provide adequate scientific docu-
mentation of efficacy and safety of their products with
the aim to improve quality and standardization of aller-
genic extracts. Therefore AIT extract should be set up
with high quality product, properly standardized and
containing sufficient doses of allergens [119].
For all these reasons the Italian Medicines Agency
(AIFA) in October 2009 organized a Working Group on
allergens, with the aim to: 1) verify the existence of an
acceptable level of quality, efficacy and safety for allergen
products currently on the market as NPP; 2) define the
registration process for allergenic extracts. To facilitate
this regulatory process, the AIFA is currently funding an
independent multicenter, prospective DBPC randomized
trial to evaluate the efficacy, safety, tolerability and cost-
effectiveness of SLIT to house dust mite in combination
with standard of care in pediatric allergic asthma.
The unmet needs and the future directions
Data from systematic reviews of meta-analyses ascertained
the efficacy of AIT in the treatment of allergic respiratory
diseases [27]. Despite this, some methodological criticisms
were evidenced: a) the amount of the administered main-
tenance dose is largely variable and established only for
few preparations [27, 60]; b) the protocols of administra-
tion are neither univocal nor standardized; c) the descrip-
tion and classification of side effects is variable among
studies, and between controlled trials and post marketing
surveys; d) more detailed studies with objective parame-
ters measured are needed in asthma [120]. All these as-
pects make difficult to compare each study with another.
In addition, the duration of treatment (that varies from 6
to 36 months) and the regimen of administration are not
well standardized. Finally, there is still a discrepancy
in the standardization methods, and the content of
major allergen(s) remains largely variable among man-
ufacturers [121, 122].
There is still room for improving AIT as far as prescrip-
tion, efficacy and safety are concerned. The molecular-
based diagnosis would certainly improve the accuracy in
AIT prescription [22, 123, 124], allowing to dissect the
genuine sensitizations and the cross-reactions due to pan-
allergens. The epicutaneous and intralymphatic routes of
administration would represent an intriguing prospective
approach, especially in the pediatric age [27]. Nonetheless,
all these approaches remain experimental.
Allergen specific-immunotherapy in pediatric clin-
ical practice (Fig. 1)
A crucial issue with AIT in clinical practice is continu-
ous communication with children and their families in
order to maintain compliance to such a long-term treat-
ment program, which lasts 3 to 5 years. Adolescents, in
particular, should be properly motivated.
It is necessary to specify that SCIT requires consider-
able efforts for the first months of treatment. Later on,
in most cases, the subcutaneous administration has a
monthly schedule and it is more easily accepted. Cur-
rently on the market there are “allergoids”, preparations
which greatly reduce the commitment of subcutaneous
administration.
As for SCIT, patients and families should be com-
pletely aware about the mode of administration of SLIT.
After the first administration, which must be made in a
controlled setting, SLIT is continued at home, therefore
parents should check the regular intake of SLIT by their
child.
Regardless of the route of AIT administration, parents
must be informed on the cost, possible side effects and ex-
pectations of AIT effectiveness. Once started, AIT must
be conducted regularly, arranging for periodic visits and
frequent alerts to the family in order to maintain compli-
ance. Based on the clinical data available, it can be
assessed with the family whether to start a course of AIT
even for milder cases of IgE-associated allergic diseases
with the primary aim to prevent the development of
asthma or new sensitizations. Currently there are no indi-
cations to prefer SLIT over SCIT. The advantages of SLIT
are a greater safety profile and an easier administration
route which does not require the presence of a doctor or a
qualified health professional except for the first dose. The
allergen choice must be based on careful medical history,
results of allergy diagnostic tests and demonstration of a
correlation between the identified allergen and symptoms.
In case of poly-sensitized patients, the causal role of each
individual allergen needs to be established in order to
choose those most clinically relevant.
For AIT treatments, the instructions given by the
manufacturer of the commercial extracts should be
followed. As a general rule, AIT involves an induction
phase (build-up) followed by a maintenance phase. SCIT
must be performed by a doctor or another healthcare
professional in a hospital or in a controlled setting, fully
equipped to deal with emergencies. Readily available are
required: adrenaline in vials or self-injectors, oxygen by
mask or nasal cannula, corticosteroids for intravenous
administration and a bag valve mask for ventilation. If
an adverse event occurs, the child must be stabilized first
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and transferred to a pediatric emergency room only
when table. The SCIT induction phase should start with
low doses. There are different protocols for SCIT induc-
tion phase which comprise different timing ranging from
days or weeks (rush and ultra-rush schemes) to months.
Once the maintenance dose is reached, it is commonly
administered every 2 weeks for at least 3 months, and
afterwards monthly After every subcutaneous injection,
patients should remain under observation for at least
30 min; furthermore, physical exercise should be avoided
in the following hours. The side of SCIT injections is
usually the side anterior or rear surface of the arm.
Concerning SLIT, the first dose should be adminis-
tered in a hospital or clinic under medical supervision.
The SLIT induction phase is usually shorter than that of
SCIT, ranging between 3 and 5 days. It is important to
specify that drops or tablets must be kept under the
tongue for 2 min and then swallowed. It is advisable that
patients keep a symptom diary to record all reactions
apparently related to the assumption of SLIT. A fix and
simple schedule of administration would increase the
compliance to the treatment.
Dosage reduction or temporary interruption of AIT
may be justified in the case of:
a) acute asthma exacerbation;
b) concurrent febrile illness;
c) moderate to severe adverse events;
d) prolonged treatment discontinuation.
Treatment can be resumed with the same maintenance
dose, if the suspension was relatively short (up to 2
weeks). In the event of more prolonged interruption,
AIT should be resumed by reducing the dose or restart-
ing the induction phase with the same initial conditions
if any. Uncontrolled asthma remains the major absolute
contraindication to both SCIT and SLIT [44].
Clinical parameters like exacerbation of symptoms or
use of relief medications can be helpful in evaluating the
effectiveness of AIT. In addition, pulmonary function tests
are crucial in evaluating children with asthma or assessing
the involvement of the lower airways in children with al-
lergic rhinitis. The repetition of skin test or specific-IgE
assay cannot replace, in clinical practice, the physician’s
judgment about the patient status undergoing AIT.
If a clinical improvement along with significant re-
duction in the use of medications is not observed
after 1 year of therapy, the indication for AIT must
be revaluated. It is therefore necessary to reassess the
appropriateness of the selection of the allergic child
and eventually the diagnosis of respiratory allergy.
After the end of treatment, children should be
checked at least once every year to verify the long-
term effectiveness of AIT.
Conclusions
AIT is the unique aetiological and immune-modifying
treatment currently available for patients suffering from
IgE-associated diseases. It should be considered in
pediatric patients, also preschool children, with rhino-
conjunctivitis and/or asthma with an ascertained IgE-
associated respiratory allergy, caused by clinically relevant
allergens. The decision to start the treatment depends
on several factors. It should be always used in associ-
ation with appropriate pharmacotherapy and for at least
3 years. AIT is not only well tolerated but also effica-
cious in the short and long-term and in prevention of
new sensitizations and development-impairment of
asthma. Concerning food allergies, based on current
evidence, we recommend to perform food OIT/SLIT
only in highly specialized centers and under strict med-
ical supervision after the informed consent has been
obtained from parents. OIT/SLIT standardized prod-
ucts are awaited. The efficacy of AIT in children and
adults with extrinsic AD is still controversial and needs
further large and well-designed studies.
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